Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [1] A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group
    Nishina, Tomohiro
    Boku, Narikazu
    Kurokawa, Yukinori
    Sasaki, Keita
    Machida, Ryunosuke
    Yoshikawa, Takaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (10) : 1100 - 1106
  • [2] Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
    Urakci, Zuhat
    Ebinc, Senar
    Tunc, Sezai
    Kalkan, Ziya
    Oruc, Zeynep
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [3] Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer
    Bilici, Ahmet
    Selcukbiricik, Fatih
    Demir, Nazan
    Ustaalioglu, Bala Basak Oven
    Dikilitas, Mustafa
    Yildiz, Ozcan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8661 - 8666
  • [4] Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice
    Laterza, Maria Maddalena
    Pompella, Luca
    Petrillo, Angelica
    Tirino, Giuseppe
    Pappalardo, Annalisa
    Orditura, Michele
    Troiani, Teresa
    Ciardiello, Fortunato
    Di Martino, Natale
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2017, 34 (11)
  • [5] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    Miles, D. W.
    Dieras, V.
    Cortes, J.
    Duenne, A. -A.
    Yi, J.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2773 - 2780
  • [6] The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
    Liu, Yu-Yin
    Tsai, Ming-Yen
    Liu, Ting-Ting
    Liu, Yueh-Wei
    Lin, Yu-Hung
    Yeh, Cheng-Hsi
    Lin, Yu-Cheng
    Chen, Yen-Hao
    BMC CANCER, 2024, 24 (01)
  • [7] Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023
    Shimozaki, Keitaro
    Ooki, Akira
    Yoshino, Koichiro
    Tamba, Mikako
    Udagawa, Shohei
    Osumi, Hiroki
    Fukuoka, Shota
    Nakayama, Izuma
    Wakatsuki, Takeru
    Ogura, Mariko
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [8] Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan
    Kashiwa, Munenobu
    Matsushita, Ryo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (07) : 895 - 903
  • [9] The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer
    Chang, Chunxiao
    Pei, Yanqing
    Xu, Jun
    Zhang, Wenyu
    Zhang, Jianbo
    Shi, Shengbin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
    Zheng, Bowen
    Lou, Fanzhuoran
    He, Yuting
    Fu, Miao
    Huang, Xintian
    Tan, Weijuan
    Chen, Quan
    Xie, Xiaowen
    Hu, Tianhui
    Xiao, Li
    CANCERS, 2025, 17 (04)
12345